Tenelia Elderly CGMS Study(TEDDY)

• Status: Active, not recruiting
• Trial end date: 2020-12-04
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy and safety of Teneligliptin in Patients aged 65 and Older with inadequately controlled type 2 diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Handok Inc.; Handok Pharmaceuticals Co., Ltd.

Criteria

Inclusion Criteria:

• Patients who are 65 years or older on screening

• Patients with type 2 diabetes mellitus

• Patients with 7.0% ≤ HbA1c ≤ 9.0% at the screening visit

• Patients with FPG < 270mg/dL on screening visit

Exclusion Criteria:

-